Member Info for mulledwine

Outlook The Group has made good progress in the first six months of this financial year; we continue to reposition ourselves in our chosen markets and have delivered strong growth in profits, while improving margins and cash generation have given us a healthy financial position at the period end. While remaining cautious in the face of the current negative economic sentiment, the Board is confident about the Group's profit outlook for the year which is in line with current market expectations.

http://www.investegate.co.uk/Article.aspx?id=201111290700099112S

WH Ireland reiterated its "buy" recommendation for Scapa (SCPA) with a 68p target price. The broker believes that the adhesive manufacturer's strategy of focusing on margin improvement rather than sales growth is the correct one in the current climate and will leave it well positioned in the event of an upturn. WH Ireland expects this to be achieved through the transition from commodity to premium businesses. The broker forecasts full year revenues of 198 million pounds, with pre-tax profits of 9.7 million pounds. Scapa shares inched up 0.25p to 49.5p.

Much has changed since the Independent's Investment Column looked at spread betting firm IG Group. For one thing, the economic outlook has turned darker, making IG's chunky prospective dividend yield of 5% (and higher on some estimates) look that much more attractive, the Indy reckons. The income, and the quality of the UK business, suddenly appears more valuable in light of the weaker trends in the global economy. Rising revenues in uncertain times, a quality franchise and a healthy dividend yield at a time when earnings across all manner of sectors are in question – make IG look like a good bet. At around 12 times forward earnings for next year, falling to under 11 times for the year after, IG is not expensive either. Take a punt on the shares, says the Indy.

Commenting on these results, Faisal Rahmatallah, Executive Chairman, said: "These results reflect progress in a difficult environment. Strong new business successes over the past 18 months have enabled us to maintain revenues, despite underlying demand weakness. We have improved value-added margins, allowing us to increase investment in business development activities, particularly in emerging markets. We have also refinanced our bank debt halfway through the period, significantly reducing our interest costs going forward. Whilst the economic environment remains challenging, the Group will continue to pursue organic growth opportunities, particularly in emerging markets. Our new business pipeline remains strong and providing the economic environment does not worsen materially the Board expects progress to be broadly in line with expectations for the rest of the financial year."

Operational highlights · Good earnings per share growth in spite of challenging economic environment · Strong cash conversion - 70% of EBITDA converted to operating cash flow · New business wins continue - 11 new key accounts won during first half year · Excellent progress with new operations in China, India and Thailand · Bank refinancing completed in July '11 reduces interest costs

Financial Review Overall these interim results reflect continued earnings growth despite a difficult macroeconomic environment. Compared to the same period last year, on an underlying basis the Group has: · Maintained revenue at £16.3m · Operating performance broadly unchanged · Increased profit before tax and earnings per share by 10.5% · Reduced net debt by £3.6m to £11.2m Value-added margins have improved compared to the same period last year and have compensated for the investment in business development activity that has been made since then. Meanwhile, unit volumes were 5% down despite a good contribution from new business. The improvement in underlying profitability was primarily related to a reduction in interest costs caused by two factors; first, total debt has been reduced over the period, and, second, a refinancing was completed in July 2011, which has resulted in a lower average interest rate being paid. Underlying operating cash flow has been good with £1.8m being generated for the six month period - this represents a 70% conversion from EBITDA. Working capital has been well managed and capital expenditure has been maintained at normal levels. In addition to cash flow from operations, we were able to realise £0.4m from the sale of a 40% stake held in a private company called Skor Srl ("Skor"), based in San Marino. This minority stake was a legacy asset from the acquisition in August 2007 of Channel Matrix Limited and had a book value of £0.03m - the profit on the sale has been classified as an exceptional gain and is also excluded from underlying profitability. Skor had a complex and inefficient long term supply and distribution arrangement with C&T Matrix Limited ("C&T") which has now been restructured to the long term benefit of the Group. Finally, the Group redeemed £0.6m of outstanding deferred consideration associated with the acquisition in March 2008 of Palagan. The transformation of the Group's balance sheet since the 2008 crisis is evident. The Company is pleased to announce that it intends to pay an interim dividend of 0.33p to all shareholders on 6 January 2012 in respect of the period ended 30 September 2011. The record date for the dividend is 9 December 2011 and the associated ex div date is 7 December 2011.

http://www.investegate.co.uk/Article.aspx?id=201111300700139973S

30th November 2011 Analyst: Richard Gill Email: richard.gill@gecr.co.uk Tel: 0207 562 3378 Plastics Capital - Solid interim results with further debt reduction and maiden dividend announced. Full year forecasts lowered due to caution over global economic slowdown. Target price lowered to 100p, stance unchanged at BUY

Commenting on the acquisition, Don Elgie, Group Chief Executive of Creston plc, said: "The Corkery Group is an excellent business with a strong track record of individual account growth and an attractive client list. The Corkery Group and Cooney/Waters are well known to one another, their cultures are similar and I am confident the increased critical mass of the combined business will benefit both operations going forward."

CONT Under the terms of the Cooney/Waters acquisition, Creston agreed a deferred consideration based on the future profit before interest and tax of the acquired businesses (the 'C/W Deferred Consideration'), of which Lenore Cooney was the sole beneficiary. As The Corkery Group will become a 100 per cent subsidiary of Cooney/Waters and be fully integrated with immediate effect, Lenore Cooney has agreed that David Corkery, The Corkery Group's founder, will become a named recipient of 47 per cent of any future payments made under the C/W Deferred Consideration. There are no changes to the maximum value of potential payments made under the C/W Deferred Consideration, which is capped at US$21 million. Founded in 1998, The Corkery Group employs 25 staff and is focused on long-term relationships with a diverse mix of clients including: International agencies, US government agencies, pharmaceutical and bio-technology companies and non-profit organisations. The Corkery Group's healthcare industry expertise spans scientific, policy and product communications, media relations, digital media, executive support and crisis management. Current clients include: American Society of Clinical Oncology, Gilead Sciences and the U.S. Centers for Disease Control and Prevention. Following the acquisition, The Corkery Group will continue to benefit from the experience and expertise of David Corkery, who will continue as a Senior Advisor. Additionally, senior members of The Corkery Group's existing management team, Karen O'Malley (President of The Corkery Group) and Greg Lugliani (Executive Vice President), will join the Cooney/Waters Group's operating board. Through adding new clients and complementary expertise and talent to the Group, as well sharing best practice and knowhow, we believe there are many synergy benefits to be leveraged by the wider Group as a result of this acquisition. Both companies will be re-located to one central location in 2012. For the financial year ended 31 December 2010, The Corkery Group reported revenues of US$9.9 million (£6.4 million) and a profit before taxation of US$0.3 million (£0.2 million) - pre any shareholder bonus dividends profit before tax was US$3.5 million (£2.2 million). As at 31 December 2010 The Corkery Group had reported gross assets of US$2.0 million (£1.3 million). For the nine months ending 30 September 2011, The Corkery Group had unaudited revenues of US$6.3 million (£4.0 million) and pre any shareholder bonus dividends a profit before interest and tax of $1.9 million (£1.2 million). This is a lower financial performance than the prior year, due to the company's resignation of a client in 2010.

Acquisition of The Corkery Group Cooney Waters LLC ('Cooney/Waters'), a subsidiary of Creston plc ('Creston' or the 'Group'), the Insight and Communications Group, today announces the acquisition of 100 per cent of the share capital of The Corkery Group, a New York based full service health and medical public relations company specialising in product and issues communications for the world's leading health organisations. Total initial cash payments amounting to US$6.0 million (£3.8 million) will be payable. As well as being immediately earnings enhancing, the acquisition of The Corkery Group strengthens the Health division and complements Cooney/Waters, the US healthcare communications specialist that was acquired by Creston last year. Following today's announcement, The Corkery Group will operate as a 100 per cent subsidiary and trading division of the Cooney/Waters Group. ....................................................................

http://www.investegate.co.uk/Article.aspx?id=201111300701020163T

Commenting on the results, Michael Rosenberg, Chairman of Pilat Media Global plc, said: "We are pleased to have announced the settlement of our dispute with Fox Television Stations Inc with the result that the Company will now be receiving a payment from them. Our Q3 revenues continued to grow on the back of increased demand from our existing client base, bringing the growth over the last nine months to over 4%. We continue to make significant investment in improving and expanding our products and this in part has enabled revenues from our existing clients to increase. We are also engaged with a number of new potential projects but these are moving forward at a slower pace than we had envisaged and this will inevitably restrict growth for this year."

esults for the nine months ended 30 September 2011 Pilat Media Global plc (AIM:PGB), the London-based supplier of business management software to the media industry around the world, today announces its results for the nine months ended 30 September 2011 and the three months to 30 September 2011 ("Q3"). Highlights: · Revenues: · Nine month revenues up 4.4% to £16.35 million (Nine month 2010: £15.67 million) · Q3 revenues up by 5.1% to £5.51 million (Q3 2010 £5.25 million) · Operating profit before impairment of receivable: · Nine months 2011 profit: £1.29 million (Nine months 2010: £1.44 million) · Q3 profit: £244,000 (Q3 2010: £53,000) · Recovery of £544,000 against impaired receivable balance as litigation with Fox Television Stations Inc is settled · Loss / profit after tax: · Nine months loss after tax: £1.33 million (Nine months 2010: profit £398,000) · Q3 profit after tax: £370,000 (Q3 2010: £54,000)

http://www.investegate.co.uk/Article.aspx?id=201111300700220165T

......................................I am confident that the outlook for African Medical remains extremely positive, as we continue to succeed in filling a crucial and niche role providing international quality healthcare for the emerging middle classes, overseas business investors, governments and health insurers in Africa. With this in mind, our sights remain firmly set on expanding our offering as we recognise that that there is significant potential for rapid expansion across the continent. Our objective is to target established private medical markets including Uganda, Kenya and Nigeria in order to enlarge the 'AMI Hospital' brand. In addition, in the near term we are also in advanced negotiations to secure control of hospital management contracts, including a contract to operate a facility in Lusaka, Zambia, and we also hope to work in conjunction with major resource companies to establish medical clinics, including the establishment of a polyclinic in the booming mining community of Tete, in northern Mozambique. Furthermore, we will be expanding our AMI Aviation product by introducing a Cessna Citation 5 aircraft for short range medical evacuations. This will complement the mid-range capability of our Dassault Falcon 20. I firmly believe that we have defined a robust growth strategy for the Group, set against a background of strong fundamentals for private healthcare in Africa. In addition, with a market capitalisation currently wholly underpinned by our net asset value, African Medical is in a strong position to rapidly build value for our shareholders. I would like to take this opportunity to thank our employees and my fellow board members for their tireless dedication, and also to our shareholders for their continued support as we look towards the Group's next phase of growth and value accretion. Peter Botha Chief Executive Officer 30 November 2011

rican Medical Investments plc ('African Medical' or 'the Company') Interim Results African Medical Investments plc, the AIM listed company operating in the African healthcare sector, announces its results for the six month period ended 31 August 2011. HIGHLIGHTS: · Successful recovery and turnaround of hospital and healthcare portfolio which consists of AMI Hospital Maputo, AMI Hospital Dar es Salaam, AMI Hospital Harare and AMI Aviation · Considerable progress towards objective of becoming a leading provider of private specialist hospitals across Africa, offering high quality in and out patient services · 180% increase in revenue for the period ended 31 August 2011 to US$5,941,000 (six month period ended 31 August 2010: US$2,099,000) · Revenue from existing business units (AMI Hospital Maputo and AMI Hospital Dar es Salaam) increased by 110% for the period ended 31 August 2011 to US$4,342,000 · 58% reduction in head office operating expenditure for the period ended 31 August 2011 to US$1,252,000 (six month period ended 31 August 2010: US$2,989,000) · Injection of US$2 million through a private placing of 61,707,130 new ordinary shares subscribed to by the Company's new Chief Executive Officer, Dr. Peter Botha · Significant progress made towards expansion strategy - new medical facility opportunities in advanced negotiations in Lusaka, Zambia, and Tete, Mozambique

http://www.investegate.co.uk/Article.aspx?id=201111300700220158T

Commenting on the results, Don Elgie, Group Chief Executive of Creston plc, said: "We have performed well during the first half, growing revenue and Headline PBT by 14 per cent and 13 per cent respectively. Our like-for-like growth has been driven by new business wins from both new and existing clients, a growing amount of which is from referrals across our agencies and divisions. "During the first half we continued to diversify, through servicing new geographies, launching new products and continuing to grow our digital business. We are confident of seeing the first half's positive momentum continue in the second half and believe our diversification does afford us some protection against market uncertainty. However, macro-economic events lead us to maintain a cautious outlook for the remainder of our financial year."